In a landmark judgment that redraws the ethical boundaries of modern medicine, the Supreme Court of India has ruled that desperation cannot be mistaken for consent. In Yash Charitable Trust & Ors. v. Union of India & Ors. (2026 INSC 96), the Court halted the commercial use of unproven stem cell therapies for Autism Spectrum Disorder (ASD), making it clear that patient autonomy does not exist in a scientific vacuum.

The case arose from a public interest litigation highlighting how private clinics were offering stem cell “treatments” for autism, charging families large sums despite the absence of proven benefit. The Court was asked to decide whether parents, acting under Article 21 of the Constitution, could choose any treatment they believed might help their child. The answer was unambiguous: choice does not automatically amount to informed consent.

What the Court Decided — and Why

At the heart of the ruling is the standard of care, a long-standing medical principle that requires doctors to follow practices accepted by the medical profession at a given time. Drawing on precedents such as the Bolam test and Jacob Mathew, the judges reaffirmed that personal belief or hope cannot replace scientific evidence. As the Court observed, a treatment unsupported by reliable medical data cannot be justified as sound practice, no matter how sincerely it is offered.

National and international health bodies, including the Indian Council of Medical Research (ICMR), have consistently found insufficient evidence to support stem cell therapy as a routine treatment for autism. On this basis, the Court upheld the National Medical Commission’s position that promoting or administering such therapy amounts to professional misconduct.

Speaking to Drug Today, Activist and Supreme Court Lawyer, Sharmistha choudhury says, “This judgment is a landmark affirmation of child rights and public health under Article 21 of the Constitution, which guarantees the right to life with dignity, safety, and health. Children with autism cannot be treated as experimental subjects, nor can parental vulnerability be converted into a commercial opportunity for unproven medical interventions. By prohibiting the commercial sale of stem cell therapy outside approved clinical trials, the Supreme Court has reaffirmed the State’s constitutional obligation to protect children from harm and exploitation.” 

When “Innovation” Becomes a Marketing Tool

A key issue before the Court was how clinics used scientific-sounding language to sidestep regulation. Terms like “autologous” (using a patient’s own cells) and “surgical procedure” were deployed to argue that these interventions were not drugs and therefore outside the Drugs and Cosmetics Act.

The Court rejected this argument. It ruled that stem cells are “substances” intended for treatment and therefore fall within the legal definition of drugs. This interpretation closes a major loophole. Whether cells are minimally or substantially processed, their use for treating a disorder brings them under regulatory oversight. In simple terms, using a patient’s own cells does not make an unproven therapy automatically safe or legal.

The Problem of Therapeutic Misconception

Perhaps the most important ethical contribution of the judgment is its clear warning against therapeutic misconception. This occurs when patients or families believe that an experimental procedure is established treatment. For parents of children with autism—often navigating uncertainty and social stigma—this misunderstanding can be powerful.

The Court noted that valid consent requires adequate information. Where scientific evidence is unclear or incomplete, doctors cannot fully explain risks and benefits. In such circumstances, the judges said, consent becomes legally and ethically hollow. As one observation put it, offering experimental interventions as treatment “creates a false sense of medical assurance”.

“The Court has rightly held that consent cannot substitute scientific validity. Under Article 21, informed consent is meaningful only when backed by evidence-based medicine. Permitting unproven therapies, even at the request of parents, would amount to a violation of a child’s fundamental right to health and bodily integrity,” Ms Choudhury said.

Autonomy Has Limits

Does this mean parents have no say in their child’s care? The Court answered this by drawing a careful distinction. Patients have the right to refuse treatment, but not an unlimited right to demand therapies that fall outside accepted medical practice. Autonomy does not override a doctor’s duty to act responsibly and ethically.

This finding empowers physicians to say no when asked to provide unvalidated interventions. It also protects families from what the Court described as a form of economic and emotional exploitation, where high fees are charged for experimental procedures without the safeguards of formal clinical trials.

What Happens Next

The ruling directs that stem cell interventions for autism can only take place within approved clinical trials, with strict oversight, ethical approval, and no charges to participants. Clinics operating outside this framework face disciplinary action. The Ministry of Health has been asked to ensure that existing patients are redirected to legitimate research institutions.

Beyond autism, the judgment sets a broader precedent. It signals that innovation in medicine must follow evidence, not precede it. Real freedom in healthcare, the Court underscored, is not the freedom to be exploited by false hope, but the right to be protected by science, ethics, and a clear standard of care.

According to Ms Choudhury, Importantly, the judgment does not obstruct scientific progress. It strengthens public health governance by directing innovation into regulated clinical trials with ethical oversight, transparency, and accountability. This constitutional balance ensures that hope is guided by science, not commerce, and that the rights of children remain paramount in healthcare policy. 

“The Supreme Court’s ruling brings India’s constitutional commitment under Article 21 in alignment with international child-rights and public-health standards. Globally accepted principles recognise that children, particularly those with disabilities, require heightened protection from medical exploitation and experimental interventions without proven benefit,” Ms Choudhury added.

By prohibiting the commercial use of stem cell therapy for autism outside approved clinical trials, the Court has reaffirmed that the child’s right to health, safety, and dignity must prevail over market-driven healthcare practices. This judgment places India firmly within the global framework of ethical medicine, where innovation is encouraged, but never at the cost of vulnerable children, she concluded.